$SIBN
SI-BONE Inc Stock $sibn

$sibn Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000145983918000009 Filed on November 29, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$15.62M	$13.38M	$11.68M
YoY Change	13.44%	14.53%
Cost Of Revenue	$1.380M	$1.221M	$1.328M
YoY Change	13.11%	-8.06%
Gross Profit	$14.24M	$12.16M	$10.36M
YoY Change	13.47%	17.43%
Gross Profit Margin	91.17%	90.88%	88.63%
Selling, General & Admin	$17.05M	$13.83M	$13.93M
YoY Change	32.07%	-0.7%
% of Gross Profit	119.73%	113.74%	134.51%
Research & Development	$1.500M	$1.373M	$1.466M
YoY Change	17.19%	-6.34%
% of Gross Profit	10.53%	11.29%	14.16%
Depreciation & Amortization	$180.0K	$200.0K	$300.0K
YoY Change	-5.26%	-33.33%
% of Gross Profit	1.26%	1.64%	2.9%
Operating Expenses	$18.55M	$15.20M	$15.39M
YoY Change	30.73%	-1.23%
Operating Profit	-$4.310M	-$3.044M	-$5.039M
YoY Change	162.8%	-39.59%
Interest Expense	-$710.0K	$1.282M	$1.005M
YoY Change	-77.95%	27.56%
% of Operating Profit
Other Income/Expense, Net	-$290.0K	-$535.0K	$317.0K
YoY Change	625.0%	-268.77%
Pretax Income	-$5.310M	-$4.790M	-$5.680M
YoY Change	8.15%	-15.67%
Income Tax
% Of Pretax Income
Net Earnings	-$5.310M	-$4.792M	-$5.683M
YoY Change	8.15%	-15.68%
Net Earnings / Revenue	-33.99%	-35.81%	-48.64%
Basic Earnings Per Share
Diluted Earnings Per Share	-$257.9K	-$196.8K	-$260.7K
COMMON SHARES
Basic Shares Outstanding	24.34M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$122.2M	$14.00M
YoY Change
Cash & Equivalents	$25.12M	$14.00M	$18.50M
Short-Term Investments	$97.10M
Other Short-Term Assets	$2.000M	$700.0K
YoY Change
Inventory	$3.343M	$3.028M
Prepaid Expenses
Receivables	$8.486M	$7.092M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$136.0M	$24.86M
YoY Change	304.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.154M	$2.048M
YoY Change	13.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$325.0K	$1.486M
YoY Change	5.18%
Total Long-Term Assets	$2.479M	$3.534M
YoY Change	12.43%
TOTAL ASSETS
Total Short-Term Assets	$136.0M	$24.86M
Total Long-Term Assets	$2.479M	$3.534M
Total Assets	$138.5M	$28.40M
YoY Change	286.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.146M	$1.790M
YoY Change	18.3%
Accrued Expenses	$6.860M	$7.152M
YoY Change	19.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$9.006M	$8.942M
YoY Change	19.47%
LONG-TERM LIABILITIES
Long-Term Debt	$38.96M	$38.90M
YoY Change	0.67%
Other Long-Term Liabilities	$360.0K	$332.0K
YoY Change
Total Long-Term Liabilities	$39.32M	$39.23M
YoY Change	1.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.006M	$8.942M
Total Long-Term Liabilities	$39.32M	$39.23M
Total Liabilities	$48.33M	$49.28M
YoY Change	3.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$157.2M	-$151.9M
YoY Change	12.49%
Common Stock	$3.000K	$1.000K
YoY Change	200.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$90.19M	-$139.4M
YoY Change
Total Liabilities & Shareholders Equity	$138.5M	$28.40M
YoY Change	286.56%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$5.310M	-$4.792M	-$5.683M
YoY Change	8.15%	-15.68%
Depreciation, Depletion And Amortization	$180.0K	$200.0K	$300.0K
YoY Change	-5.26%	-33.33%
Cash From Operating Activities	-$6.320M	-$2.530M	-$3.970M
YoY Change	56.44%	-36.27%
INVESTING ACTIVITIES
Capital Expenditures	-$160.0K	-$60.00K	-$100.0K
YoY Change	45.45%	-40.0%
Acquisitions
YoY Change
Other Investing Activities	-$96.88M
YoY Change
Cash From Investing Activities	-$97.05M	-$60.00K	-$100.0K
YoY Change	88127.27%	-40.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	114.5M	420.0K	-910.0K
YoY Change	1239.42%	-146.15%
NET CHANGE
Cash From Operating Activities	-6.320M	-2.530M	-3.970M
Cash From Investing Activities	-97.05M	-60.00K	-100.0K
Cash From Financing Activities	114.5M	420.0K	-910.0K
Net Change In Cash	11.15M	-2.170M	-4.980M
YoY Change	153.41%	-56.43%
FREE CASH FLOW
Cash From Operating Activities	-$6.320M	-$2.530M	-$3.970M
Capital Expenditures	-$160.0K	-$60.00K	-$100.0K
Free Cash Flow	-$6.160M	-$2.470M	-$3.870M
YoY Change	56.74%	-36.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001459839
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24335690	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	SI-BONE, INC.
	dei	Entity Small Business EntitySmallBusiness	true
CY2017Q4	sibn	Common Stock Equivalent Shares Stock Options Outstanding CommonStockEquivalentSharesStockOptionsOutstanding	3001929	shares
CY2018Q3	sibn	Common Stock Equivalent Shares Stock Options Outstanding CommonStockEquivalentSharesStockOptionsOutstanding	2711667	shares
CY2018Q3	sibn	Convertible Preferred Stock Minimum Public Offering For Conversion ConvertiblePreferredStockMinimumPublicOfferingForConversion	50000000	USD
CY2018Q3	sibn	Convertible Preferred Stock Minimum Public Offering Per Share For Conversion ConvertiblePreferredStockMinimumPublicOfferingPerShareForConversion	30.0996
CY2018Q3	sibn	Debt Instrument Covenant Minimum Cash Balance DebtInstrumentCovenantMinimumCashBalance	5000000	USD
CY2017Q4	sibn	Equity And Temporary Equity Common Stock Equivalent Shares Issued And Reserved For Future Issuance EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance	18986360	shares
CY2018Q3	sibn	Equity And Temporary Equity Common Stock Equivalent Shares Issued And Reserved For Future Issuance EquityAndTemporaryEquityCommonStockEquivalentSharesIssuedAndReservedForFutureIssuance	18986360	shares
CY2017Q4	sibn	Equity And Temporary Equity Shares Issued And Reserved For Future Issuance EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance	18787177	shares
CY2018Q3	sibn	Equity And Temporary Equity Shares Issued And Reserved For Future Issuance EquityAndTemporaryEquitySharesIssuedAndReservedForFutureIssuance	18787177	shares
	sibn	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	0	USD
	sibn	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	865000	USD
CY2017Q4	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	65000	USD
CY2017Q4	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	100000	USD
CY2018Q3	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	400000	USD
CY2018Q3	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	359000	USD
	sibn	Notes Receivable Forgiveness NotesReceivableForgiveness	400000	USD
	sibn	Notes Receivable Forgiveness NotesReceivableForgiveness	437000	USD
	sibn	Notes Receivable Forgiveness NotesReceivableForgiveness	0	USD
CY2017Q3	sibn	Offering Costs Expensed OfferingCostsExpensed	1300000	USD
	sibn	Offering Costs Expensed OfferingCostsExpensed	1300000	USD
CY2017Q4	sibn	Preferred Stock Warrant Liability PreferredStockWarrantLiability	422000	USD
CY2018Q3	sibn	Preferred Stock Warrant Liability PreferredStockWarrantLiability	1103000	USD
CY2017Q4	sibn	Sales And Product Warranty Accrual Current SalesAndProductWarrantyAccrualCurrent	100000	USD
CY2017Q4	sibn	Sales And Product Warranty Accrual Current SalesAndProductWarrantyAccrualCurrent	149000	USD
CY2018Q3	sibn	Sales And Product Warranty Accrual Current SalesAndProductWarrantyAccrualCurrent	52000	USD
CY2018Q3	sibn	Sales And Product Warranty Accrual Current SalesAndProductWarrantyAccrualCurrent	100000	USD
	sibn	Sales Credit Reserve Period SalesCreditReservePeriod	P1Y
CY2017Q4	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	16117	shares
CY2018Q3	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	78757	shares
	sibn	Standard Product Warranty Term StandardProductWarrantyTerm	P1Y
CY2018Q3	sibn	Temporary Equity Shareholder Approval Minimum Shares Outstanding TemporaryEquityShareholderApprovalMinimumSharesOutstanding	277778	shares
	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	91000	USD
	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	64000	USD
	sibn	Write Off Of Initial Public Offering Costs WriteOffOfInitialPublicOfferingCosts	1292000	USD
	sibn	Write Off Of Initial Public Offering Costs WriteOffOfInitialPublicOfferingCosts	0	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1814000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1790000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7416000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7092000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5724000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7152000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	341000	USD
CY2018Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	858000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3022000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3196000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	402000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	431000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9943000	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12003000	USD
CY2017Q3	us-gaap	Advertising Expense AdvertisingExpense	200000	USD
	us-gaap	Advertising Expense AdvertisingExpense	600000	USD
CY2018Q3	us-gaap	Advertising Expense AdvertisingExpense	200000	USD
	us-gaap	Advertising Expense AdvertisingExpense	500000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	268000	USD
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	264000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	235000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	194000	USD
CY2017Q4	us-gaap	Assets Assets	35834000	USD
CY2018Q3	us-gaap	Assets Assets	28395000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	33629000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	24861000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	35000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27900000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18500000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22408000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14004000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9400000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8404000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	280876	shares
CY2018Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	280876	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	19333333	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	19333333	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3603140	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3912907	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3603140	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3912907	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5708000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18194000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4796000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12111000	USD
CY2017Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1328000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3894000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1221000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3451000	USD
CY2018Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	40000000	USD
CY2018Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1101000	USD
CY2017Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2018Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1200000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	300000	USD
	us-gaap	Depreciation Depreciation	800000	USD
CY2018Q3	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	817000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	536000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.64
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.26
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.29
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.34
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	154000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-52000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3732000	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3968000	USD
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1900000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-235000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	681000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-681000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	422000	USD
CY2018Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1103000	USD
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-172000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-95000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4071000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10808000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3226000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8198000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	10355000	USD
	us-gaap	Gross Profit GrossProfit	30320000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	12160000	USD
	us-gaap	Gross Profit GrossProfit	36305000	USD
CY2017	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1447000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-884000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	405000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-357000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1023000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1844000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1146000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	458000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	43000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-495000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	1005000	USD
	us-gaap	Interest Expense InterestExpense	2925000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	1282000	USD
	us-gaap	Interest Expense InterestExpense	3826000	USD
	us-gaap	Interest Paid Net InterestPaidNet	2473000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3147000	USD
CY2018Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	38899000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4310000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	627000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-370000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-777000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	831000	USD
CY2018Q3	us-gaap	Interest Payable Current InterestPayableCurrent	1176000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	2553000	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	3028000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	44000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	117000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	69000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	199000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	46664000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	49276000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35834000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28395000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7538000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8942000	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	38700000	USD
CY2018Q3	us-gaap	Long Term Debt LongTermDebt	38899000	USD
CY2018Q3	us-gaap	Long Term Debt LongTermDebt	38900000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	17778000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	17778000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4444000	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2018Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	38704000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13494000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8200000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8202000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5683000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18134000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-4792000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12140000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	15394000	USD
	us-gaap	Operating Expenses OperatingExpenses	46029000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	15204000	USD
	us-gaap	Operating Expenses OperatingExpenses	43963000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5039000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15709000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3044000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7658000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	5722000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	781000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	828000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	951000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1007000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1921000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	234000	USD
CY2017Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	700000	USD
CY2018Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	140000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	278000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	309000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1486000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-25000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-60000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	29000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	332000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	317000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	383000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-535000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-855000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1292000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	288000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	370000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	777000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1252000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	737000	USD
	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	5426000	USD
	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	176000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	915000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4918000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5244000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1896000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2048000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	8000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-3000	USD
CY2017Q4	us-gaap	Purchase Obligation PurchaseObligation	100000	USD
CY2018Q3	us-gaap	Purchase Obligation PurchaseObligation	300000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1466000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4234000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1373000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3875000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-139724000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151864000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151900000	USD
CY2017Q3	us-gaap	Revenues Revenues	11683000	USD
	us-gaap	Revenues Revenues	34214000	USD
CY2018Q3	us-gaap	Revenues Revenues	13381000	USD
	us-gaap	Revenues Revenues	39756000	USD
CY2017Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	466000	USD
CY2018Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	461000	USD
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9857000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	30987000	USD
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10605000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	31890000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1038000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1081000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	29654	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	10149	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	960000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	54278	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	73783	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3585000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23957000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3001929	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2711667	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.15
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.12
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	15271000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1639606	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.65
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	22285000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2489664	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.01
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.11
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4.77
CY2018Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.88
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.51
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M12D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	309767	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-129378000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	-139429000	USD
CY2017Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	118548000	USD
CY2018Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	118548000	USD
CY2017Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	119194000	USD
CY2018Q3	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	119194000	USD
CY2017Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	12104749	shares
CY2018Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	12104749	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3712876	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3638905	shares
CY2017Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	11871578	shares
CY2018Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	11871578	shares
CY2017Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11871578	shares
CY2018Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11871578	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3475628	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3450252	shares
	us-gaap	Advertising Cost Policy Expensed Advertising Cost AdvertisingCostPolicyExpensedAdvertisingCost	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising Expenditures</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cost of advertising is expensed as incurred.</font></div></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company’s cash and cash equivalents are deposited with financial institutions in the United States and in Europe; the majority of the Company’s cash and cash equivalents are deposited with a single financial institution in the United States. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</font></div></div>
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company and Nature of Business</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SI-BONE, Inc. (the “Company”) was incorporated in the state of Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its iFuse Implant System, or iFuse, in 2009 in the United States, in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reverse Stock Split</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company's board of directors and stockholders approved a 1-for-18 reverse stock split of the Company's common stock and redeemable convertible preferred stock, which was effected on October 4, 2018. The par value of the common stock and redeemable convertible preferred stock was not adjusted as a result of the reverse split. All issued and outstanding share and per share amounts of common stock, redeemable convertible preferred stock, stock options, and warrants included in the accompanying consolidated financial statements have been adjusted to reflect this reverse stock split for all periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 16, 2018, the Company’s Registration Statement on Form S-1 (File No. 333-227445) relating to the initial public offering (IPO) of its common stock was declared effective by the Securities and Exchange Commission (SEC). Pursuant to such Registration Statement, the Company sold </font><font style="font-family:inherit;font-size:10pt;">8,280,000</font><font style="font-family:inherit;font-size:10pt;"> shares at an initial public offering price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$113.7 million</font><font style="font-family:inherit;font-size:10pt;"> to the Company, net of underwriting discounts and commissions and offering costs. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the IPO, the Company's outstanding shares of redeemable convertible preferred stock were automatically converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">12,066,654</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and the Company's outstanding warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">156,550</font><font style="font-family:inherit;font-size:10pt;"> shares of redeemable convertible preferred stock were automatically converted into warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">284,983</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, resulting in reclassification of the related redeemable convertible preferred stock warrant liability of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> in additional paid-in-capital.</font></div></div>
	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force and distributors throughout the United States and Europe.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC Topic 605, Revenue Recognition (“ASC 605”), the Company recognizes revenue when persuasive evidence of an arrangement exists, title and risk of loss has transferred to the customer, the sales price is fixed or determinable, and collectability is reasonably assured. For the majority of product sales where the Company’s sales representative delivers the product at the point of implantation at hospitals or other medical facilities, the Company recognizes revenue related to product sales upon completion of the procedure and authorization by the customer. Revenue is recognized upon receipt of a purchase agreement or agreement on pricing terms with the customer and when all other revenue recognition criteria are met. For the remaining sales, which include distributor and hospital sales where the product is ordered in advance of a procedure and a valid purchase order has been received, the Company recognizes revenue based upon shipping or delivery terms, which represents the point in time when the customer has taken ownership and assumed risk of loss and the required revenue recognition criteria are met. Such customers are obligated to pay within specified terms regardless of when or if they ever sell or use the products, and the Company has no post-delivery obligations.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant accounting estimates and management judgments reflected in the consolidated financial statements include: fair value of assets and liabilities; analysis of the allowance for doubtful accounts; inventory valuation; valuation of deferred tax assets, including related valuation allowances; fair value of common stock and redeemable convertible preferred stock warrants; stock-based compensation; and useful lives of long lived assets. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001459839-18-000009-index-headers.html	Edgar Link	pending
0001459839-18-000009-index.html	Edgar Link	pending
0001459839-18-000009.txt	Edgar Link	pending
0001459839-18-000009-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sibn-20180930.xml	Edgar Link	completed
sibn-20180930.xsd	Edgar Link	pending
sibn-20180930_cal.xml	Edgar Link	unprocessable
sibn-20180930_def.xml	Edgar Link	unprocessable
sibn-20180930_lab.xml	Edgar Link	unprocessable
sibn-20180930_pre.xml	Edgar Link	unprocessable
sibn-ex311_930201810xq.htm	Edgar Link	pending
sibn-ex312_930201810xq.htm	Edgar Link	pending
sibn-ex321_930201810xq.htm	Edgar Link	pending
sibn930201810-q.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SIBN
SI-BONE Inc Stock $sibn

2018 Q4 Form 10-Q Financial Statement

#000145983918000009 Filed on November 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN SI-BONE Inc Stock $sibn

2018 Q4 Form 10-Q Financial Statement

#000145983918000009 Filed on November 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN
SI-BONE Inc Stock $sibn